Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Nathaly Arndtz-Wiedemann"'
Autor:
Richard N Greenberg, Christine M Hay, Jack T Stapleton, Thomas C Marbury, Eva Wagner, Eva Kreitmeir, Siegfried Röesch, Alfred von Krempelhuber, Philip Young, Richard Nichols, Thomas P Meyer, Darja Schmidt, Josef Weigl, Garth Virgin, Nathaly Arndtz-Wiedemann, Paul Chaplin
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157335 (2016)
BACKGROUND:Modified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN® (MVA
Externí odkaz:
https://doaj.org/article/fc2b41725d244487b4da1c0519dc89df
Autor:
Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin
Publikováno v:
PLoS ONE, Vol 10, Iss 10, p e0138348 (2015)
Replicating smallpox vaccines can cause severe complications in individuals with atopic dermatitis (AD). Prior studies evaluating Modified Vaccinia Ankara virus (MVA), a non-replicating vaccine in humans, showed a favorable safety and immunogenicity
Externí odkaz:
https://doaj.org/article/842751fd6ae54b48bb6e090f2e1f0bdb
Autor:
Richard N Greenberg, Maria Yadira Hurley, Dinh V Dinh, Serena Mraz, Javier Gomez Vera, Dorothea von Bredow, Alfred von Krempelhuber, Siegfried Roesch, Garth Virgin, Nathaly Arndtz-Wiedemann, Thomas Peter Meyer, Darja Schmidt, Richard Nichols, Philip Young, Paul Chaplin
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0142802 (2015)
Externí odkaz:
https://doaj.org/article/b47273e0fd7145fc972bb2c18d9a3822
Autor:
Eva-Maria Zitzmann-Roth, Frank von Sonnenburg, Stephan de la Motte, Nathaly Arndtz-Wiedemann, Alfred von Krempelhuber, Nadine Uebler, Jens Vollmar, Garth Virgin, Paul Chaplin
Publikováno v:
PLoS ONE, Vol 10, Iss 4, p e0122653 (2015)
BACKGROUND:Conventional smallpox vaccines based on replicating vaccinia virus (VV) strains (e.g. Lister Elstree, NYCBOH) are associated with a high incidence of myo-/pericarditis, a severe inflammatory cardiac complication. A new smallpox vaccine can
Externí odkaz:
https://doaj.org/article/e90ec34ac0f7497ba1a3ff2f6e9ecceb
Autor:
Siegfried Roesch, Eva Kreitmeir, Darja Schmidt, Richard A. Nichols, Garth Virgin, Richard N. Greenberg, Philip M. Young, Christine M. Hay, Alfred von Krempelhuber, Thomas Meyer, Eva Wagner, Paul Chaplin, Josef Weigl, Nathaly Arndtz-Wiedemann, Thomas C. Marbury, Jack T. Stapleton
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 6, p e0157335 (2016)
PLoS ONE, Vol 11, Iss 6, p e0157335 (2016)
Background Modified Vaccinia Ankara MVA-BN® is a live, highly attenuated, viral vaccine under advanced development as a non-replicating smallpox vaccine. In this Phase II trial, the safety and immunogenicity of Modified Vaccinia Ankara MVA-BN® (MVA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6650bc2e41ca4a2e6a028d0c443945a2
https://pubmed.ncbi.nlm.nih.gov/27327616
https://pubmed.ncbi.nlm.nih.gov/27327616
Autor:
Edgar Turner Overton, Jack Stapleton, Ian Frank, Shawn Hassler, Paul A Goepfert, David Barker, Eva Wagner, Alfred von Krempelhuber, Garth Virgin, Josef Weigl, Thomas Peter Meyer, Jutta Müller, Nicole Bädeker, Robert Grünert, Philip Young, Siegfried Rösch, Jane Maclennan, Nathaly Arndtz-Wiedemann, Paul Chaplin
Publikováno v:
Open Forum Infectious Diseases
BackgroundFirst- and second-generation smallpox vaccines are contraindicated in individuals infected with human immunodeficiency virus (HIV). A new smallpox vaccine is needed to protect this population in the context of biodefense preparedness. The f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c4628daac48cfdb416dcf8f8c6296e9
http://europepmc.org/articles/PMC4567089
http://europepmc.org/articles/PMC4567089